In a recent issue of *Nature,* two groups describe the process of cancer immunoediting whereby an individual is protected from cancer though the elimination and immunogenic modification of cancer cells. Matsushita and colleagues[@R1] use whole-exon sequencing of chemically induced mouse sarcomas to obtain evidence for T cell-mediated immunoselection. The authors characterized mutations in immunodeficient mice and thereby elegantly identified a tumor rejection antigen. Further it was demonstrated that T cell-dependent immunoselection is a crucial mechanism underlying the outgrowth of tumor cells. This exciting study was published alongside a study from DuPage et al.,[@R2] demonstrating that immunosurveillance and immunoediting can occur in an oncogene-driven endogenous tumor model provided that the tumors carry strong neo-antigens that are not present in the host. DuPage and colleagues showed that loss of tumor antigen expression or presentation on Class I MHC molecules was necessary and sufficient for immunoediting to occur. These exciting animal studies highlight the importance of tumor-specific (mutated) antigens and illustrate the importance of T cells in the immunoselection process. Such approaches may facilitate the development of individualized cancer immunotherapies directed against patient-specific mutated tumor antigens. This is intriguing since only a few commonly shared mutated T-cell antigens have been described, e.g., mutated BRAF[@R3]^,^[@R4] and RAS.[@R5] Much focus has been recently on the constitutively activating V600E BRAF mutation in melanoma due to the approval of a specific BRAF inhibitor (vemurafenib) to treat BRAF^V600E^-positive melanoma.[@R6] A few years ago, both spontaneous CD8^+^ and CD4^+^ T-cell responses was described against the V600E mutation in melanoma patients.[@R3]^,^[@R4] These responses were mutation specific as the corresponding epitopes derived from wild type BRAF were not recognized by the T cells. Even more noteworthy, however, was the observation that in two of the patients carrying BRAF^V600E^-positive primary tumors, the V600E mutation could not be detected in any of the evolving metastases.[@R3] The expression of mutant BRAF is important for the maintenance of the malignant phenotype. Thus, the loss of BRAF^V600E^ during disease development suggested an active immunoselection of melanoma cells with a wild type *BRAF* genotype.[@R3] A similar observation was made in another study describing HLA-A2-restricted T-cell responses against the V600E mutation in melanoma patients.[@R7] Although these clinical observations only are of anecdotal character, they suggest that the loss of the mutated *BRAF* genotype during the progression from primary to metastatic disease in melanoma patients exhibiting BRAF^V600E^-specific T-cell responses is caused by an active immunoselection of non-mutated melanoma by the host, especially in light of the recent publication in *Nature*. Taken together, these findings underline the potential of truly tumor-specific antigens for cancer immunotherapy.
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